Dawnrays Pharmaceutical (Holdings) Ltd

Dawnrays Pharmaceutical (Holdings) Ltd

Health CarePharmaceuticals and Biotechnology
  • Price (HKD)1.05
  • Today's Change-0.02 / -1.87%
  • Shares traded212.00k
  • 1 Year change-34.78%
  • Beta0.6919
Data delayed at least 15 minutes, as of Sep 29 2022 09:09 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Events & Activity

  • 2348:HKG trading volume exceeds daily average by +151.74%
  • 2348:HKG price reached a new 52-week low of 1.03 at 16:19 BST
  • 2348:HKG price moved over +1.89% to 1.08

Key statistics

Dawnrays Pharmaceutical (Holdings) Ltd (2348:HKG) set a new 52-week low during today's trading session when it reached 1.03. Over this period, the share price is down -37.50%.
52-week range
1.03Sep 29 20221.76Nov 02 2021
Markit short selling activity
Previous close1.07
Average volume297.70k
Shares outstanding1.50bn
Free float585.90m
P/E (TTM)4.03
Market cap1.60bn HKD
EPS (TTM)0.2654
Annual div (ADY)0.08
Annual div yield (ADY)7.48%
Div ex-dateSep 20 2022
Div pay-dateOct 05 2022
Data delayed at least 15 minutes, as of Sep 29 2022 09:09 BST.
More ▼
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.
Markit Short Selling Activity © Markit. All rights reserved.
Although Markit has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of Markit on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.